Price
478.35
+3.96%52W Range
Market Cap
₹1,407.83 Cr
Traded: ₹4.36 Cr (0.31%) 0.0x
Free Float: ₹423.05 Cr (1.03% of FF traded)
Volume · 60D trend
92.28 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +13.0% | +7.0% | +13.0% | -- | -- | Stable |
| Return | +24.0% | +9.0% | +46.0% | +40.0% | -- | Stable |
| Sales | +13.0% | +7.0% | +14.0% | -- | -3.0% | Stable |
| Profit | +51.0% | +7.0% | +65.0% | -- | -48.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 122 | 122 | 137 | 130 | 136 | 140 | 156 | 95 | 78 | 97 | 99 | 57 | 82 | 105 | 55 | 98 |
| Expenses | 104 | 102 | 112 | 104 | 108 | 103 | 103 | 76 | 77 | 92 | 74 | 71 | 72 | 86 | 65 | 95 |
| Operating Profit | 18 | 20 | 25 | 27 | 28 | 37 | 53 | 19 | 1 | 5 | 25 | -14 | 11 | 19 | -10 | 3 |
| OPM % | 14.8% | 16.4% | 18.2% | 20.5% | 20.7% | 26.4% | 34.0% | 19.8% | 1.0% | 5.5% | 25.4% | -24.4% | 13.3% | 18.0% | -18.0% | 3.0% |
| Other Income | 4 | 14 | 1 | 5 | 9 | 4 | 2 | 3 | 3 | 5 | 3 | -6 | 2 | -8 | -19 | 3 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 5 | 4 | 5 | 6 | 5 | 5 |
| Depreciation | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 9 |
| Profit Before Tax | 15 | 26 | 17 | 24 | 28 | 32 | 45 | 12 | -6 | 1 | 16 | -29 | 2 | -1 | -41 | -8 |
| Tax % | 35.1% | 29.0% | 31.2% | 25.2% | 23.1% | -4.2% | 16.4% | 5.9% | 0.0% | 884.6% | 37.8% | 0.0% | 0.0% | 373.0% | -8.0% | 6.0% |
| Net Profit | 10 | 19 | 12 | 18 | 22 | 33 | 38 | 11 | -6 | -7 | 10 | -29 | 2 | -5 | -38 | -8 |
| Exceptional Items | -- | 9 | -2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7 | 0 | -9 | -19 | 0 |
| EPS (Rs) | 3.3 | 6.5 | 4.3 | 6.1 | 7.4 | 11.7 | 12.5 | 3.9 | -2.0 | -2.4 | 3.4 | -9.7 | 0.6 | -1.4 | -12.7 | -2.8 |
| Sales Growth (YoY) | -10.6% | -13.1% | -12.2% | 37.0% | 74.4% | 43.7% | 58.1% | 67.0% | -5.2% | -7.3% | 80.0% | -41.9% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 0.2% | -11.5% | 5.5% | -4.4% | -2.6% | -10.6% | 64.7% | 21.6% | -19.7% | -1.6% | 73.9% | -31.0% | -21.5% | 90.9% | -43.9% | -- |
| OP Growth (YoY) | -36.0% | -45.9% | -53.1% | 41.9% | 3430.0% | 586.8% | 112.0% | 235.0% | -92.7% | -71.7% | 351.3% | -563.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | -9.7% | -19.9% | -6.3% | -5.7% | -23.6% | -30.6% | 183.7% | 2247.5% | -85.1% | -78.6% | 280.7% | -227.3% | -42.5% | 290.0% | -433.3% | -- |
| Profit Growth (YoY) | -- | -63.0% | -62.0% | 59.0% | 475.0% | 596.0% | 275.0% | 154.0% | -418.0% | -2133.0% | 154.0% | -163.0% | 171.0% | -104.0% | -125.0% | -280.0% |
| EPS Growth (YoY) | -55.4% | -44.2% | -65.6% | 58.7% | 474.8% | 594.9% | 274.3% | 139.9% | -419.4% | -68.6% | 126.4% | -252.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -49.2% | 51.3% | -29.8% | -17.3% | -36.5% | -6.9% | 224.0% | 295.4% | 16.1% | -170.4% | 134.5% | -1664.5% | 144.3% | 89.0% | -361.8% | -- |
| OP Margin | 14.8% | 16.4% | 18.2% | 20.5% | 20.7% | 26.4% | 34.0% | 19.8% | 1.0% | 5.5% | 25.4% | -24.4% | 13.3% | 18.1% | -18.2% | 3.1% |
| Net Margin | 7.8% | 15.3% | 8.8% | 13.8% | 15.8% | 23.8% | 24.2% | 11.7% | -7.6% | -7.3% | 10.1% | -51.1% | 2.7% | -4.8% | -69.1% | -8.2% |
| Material Cost % | 34.5% | 34.3% | 37.6% | 35.8% | 38.1% | 37.8% | 28.9% | 31.4% | 37.4% | 38.9% | 31.9% | 54.8% | 35.9% | 42.0% | 40.6% | 47.7% |
| Employee Cost % | 18.9% | 17.5% | 15.1% | 15.5% | 14.9% | 12.1% | 10.8% | 16.3% | 20.2% | 15.3% | 14.8% | 25.3% | 17.8% | 11.9% | 26.8% | 15.3% |
| P/S | 2.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 23.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.47 | 3.97 | -- | 2.17 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation of investor meeting to be held on August 21, 2026.
Revision in credit rating.
Newspaper publication of Unaudited financial results for quarter ended June 30, 2026.
Outcome of 74th Annual General Meeting.
Declaration of voting results of the 74th Annual General Meeting.
Scrutinizers report of 74th Annual General Meeting.
Presentation for shareholders at 74th Annual General Meeting (''AGM'')
Earnings presentation - Q1/FY27
Press release regarding unaudited financial results of Q1FY27.
Unaudited financial results for quarter ended June 30, 2026.
Outcome of Board meeting and unaudited financial results - June 30, 2026.
Intimation of investor(s) meeting(s).
Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve unaudited financial results ....
Intimation of investor meeting
Annual Report for Financial Year 2025-26.
Business Responsibility and Sustainability Reporting for Financial Year 2025-26.
Notice of the 74th Annual General Meeting of Fermenta Biotech Limited to be held on August 11, 2026.
Intimation of investor(s) meeting to be held on July 23, 2026.
Intimation of investor(s) meeting to be held on July 22, 2026.
Clarification on price movement in the Company''s shares.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith photocopy of the Newspaper advertisement published pertaining ....
The Exchange has sought clarification from Fermenta Biotech Ltd on July 16, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026.
Press Release regarding receipt of FSSAI Approval for the Company''s Vitamin D3 (Cholecalciferol) - Plant Source.
Fermenta Biotech Limited has received approval from Food Safety and Standards Authority of India (FSSAI) for Company''s product Vitamin D3 (Cholecalciferol) - Plant Source.
Notice of the closure of Trading window.
Press release regarding the Company being ranked 7th nationwide in the Top 50 category as part of India''s Great Mid-size workplaces 2026 by Great Place To Work.
Newspaper publication for notice for special window for transfer and dematerialisation of physical securities.
Investor meeting intimation for June 26, 2026.
Intimation of investor meeting to be held on June 22, 2026.
Application to National Stock Exchange of India Limited for seeking approval for listing and trading of the Company''s equity shares.
Newspaper publication regarding Saksham Niveshak campaign.
Intimation for Investor meet on June 15, 2026.
Intimation of investor meeting of June 12, 2026.
Investor presentation for Q4/FY26
Publication of audited financial results for the quarter and financial year ended March 31, 2026.
Audited Financial Statements (Standalone and Consolidated) for quarter & year ended March 31, 2026 along with auditors report thereon, along with information for AGM and Dividend
Recommendation of final dividend subject to approval of shareholders.
Intimation regarding proposed re-appointment of director pursuant to retirement by rotation, grant of stock options, application to NSE.
Press release regarding audited financial results of FY26.
Annual General Meeting, Financial Results and Dividend
Intimation of investor meeting.
Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve audited financial results ....
Publication of IEPF related notice for equity shareholders
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Newspaper Publication for Notice for Special window for Transfer and Dematerialisation of Physical Securities.
The Company''s shares have been admitted by NSE under ''Permitted to trade'' category on National Stock Exchange (Capital Market Segment).
Certificate under regulation 74(5) pf SEBI (DP), Regulations, 2018 for quarter ended March 31, 2026.
Notice of closure of trading window
Held by ETFs
1 ETFs hold FERMENTA · sorted by weight
Held by Mutual Funds
1 schemes hold FERMENTA · sorted by weight